Resources with keywords: Monkeypox
A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox
The high proportion of children with suspected mpox reported in the current outbreak is likely due to a number of factors, including spread within and between close households, younger population demographics in impacted countries, misdiagnosis of other diseases (such as measles), poor sanitary conditions, limited access to health services, and a high level of food insecurity and malnutrition.
MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic.
Gigante CM, Takakuwa J, McGrath D, et al.
Tecovirimat is the first-line drug for treatment of orthopoxvirus infection (e.g., smallpox and mpox). Viral mutations that render the drug ineffective can develop during treatment.
This is a Health Alert Network (HAN) Health Update to provide additional information about the ongoing outbreak of clade I monkeypox virus (MPXV), the virus that causes mpox, in Central and Eastern Africa
Includes recommendations for vaccination of health care workers, specimen collection and infection control.
The FDA approved a new indication for ACAM2000, to include the prevention of mpox disease in individuals determined to be at high risk for mpox infection. ACAM2000 has been approved since 2007 for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection. ACAM2000 is a live replicating vaccinia virus vaccine.
Choi Y, Jeon E, Kim T, Choi S, Moon SM, Song K, et al.
This report includes occupational exposure of MPOX to HCW
